Can obinutuzumab help an elderly person with podocytopathy and nephrotic syndrome?
Obinutuzumab is a newer anti-CD20 antibody that targets B cells. For an elderly person with podocytopathy (a kidney podocyte disorder) and nephrotic syndrome, the evidence is limited but promising. A 2026 case report describes a 76-year-old man who achieved complete remission of proteinuria and normal kidney function within one month after obinutuzumab treatment, sustained at one-year follow-up 37. However, this is only one case, and obinutuzumab is not yet standard therapy for this condition.
What the research says
A 2026 case report details a 76-year-old man with nephrotic syndrome, acute kidney injury, and suspected B-cell lymphoproliferative disorder who was treated with obinutuzumab. He achieved complete remission of proteinuria and normalization of renal function within one month, and the benefit lasted at least one year 37. The authors note this is the first reported case of obinutuzumab for podocytopathy with concurrent suspected B-cell disorder 37.
Another case report from 2024 describes a 33-year-old woman with FSGS (a type of podocytopathy) who had failed rituximab but achieved complete remission after obinutuzumab 5. This suggests obinutuzumab may work even when rituximab does not, possibly due to deeper B-cell depletion 5.
In a separate report, two patients with CLL and nephrotic syndrome (due to MPGN) also responded to obinutuzumab combined with venetoclax, with resolution of nephrotic syndrome within six weeks 6. While these patients had a different underlying disease, the response supports obinutuzumab's potential in B-cell-related kidney disease.
Rituximab, a related anti-CD20 drug, has been used in nephrotic syndrome, but it can cause serum sickness (fever, joint pain, rash) in some patients 4. Obinutuzumab may have a different safety profile, but data in elderly patients are very limited.
What to ask your doctor
- Could obinutuzumab be an option for my podocytopathy and nephrotic syndrome, given my age and other health conditions?
- What are the potential side effects of obinutuzumab, especially for someone my age?
- How does obinutuzumab compare to rituximab or other treatments for my specific kidney condition?
- Is there any evidence that obinutuzumab works better in patients with an underlying B-cell disorder?
- What monitoring would be needed if I were to try obinutuzumab?
This question is drawn from common patient questions about Nephrology and answered using cited medical research. We do not provide individualized advice.